Business Trip

59 Episodo

1. The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)

   Publicado: 5/6/2022
2. Empowering the next wave of psychedelic therapists: Journey Clinical

   Publicado: 23/5/2022
3. Osmind and the future of electronic health records in psychedelic medicine

   Publicado: 18/4/2022
4. Palo Santo on investing in 2nd gen psychedelics and public markets

   Publicado: 21/3/2022
5. Designing psychedelic mindstates, with Mindstate Design Labs

   Publicado: 10/2/2022
6. PsyMed Ventures, our venture fund to invest in psychedelic medicine & mental health tech

   Publicado: 10/1/2022
7. MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy

   Publicado: 24/11/2021
8. On transformational ketamine therapy and running an integrative psychedelic clinic

   Publicado: 28/10/2021
9. The new frontiers of DMT therapies

   Publicado: 6/10/2021
10. Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde

    Publicado: 13/8/2021
11. Analyzing the atai Life Sciences IPO

    Publicado: 10/6/2021
12. A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx

    Publicado: 4/5/2021
13. Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney

    Publicado: 16/3/2021
14. How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka

    Publicado: 24/2/2021
15. From serving medicine to company founder: NANA founder Flor Bollini

    Publicado: 5/1/2021
16. Helping psychedelic practitioners through software: Maya Health CEO David Champion

    Publicado: 19/10/2020
17. How to invest in psychedelic companies: Vine Ventures' Founder Ryan Zurrer

    Publicado: 17/9/2020
18. Building a psychedelic media company: DoubleBlind's Shelby Hartman and Madison Margolin

    Publicado: 13/8/2020
19. Dylan Beynon: ketamine-assisted therapy for anxiety and depression

    Publicado: 21/6/2020